Decera Clinical Education Oncology Podcast

In this episode, Jeremy S. Abramson, MD, MMSc, discusses highlights of the key data from ASH 2020 on the treatment of patients with lymphomas/CLL, with topics including: Approved and Investigational Targeted Therapeutics for CLL   Investigational CAR T-Cell Therapy for Indolent Lymphomas, CLL, and Mantle Cell Lymphoma Bispecific Antibodies and Other Investigational Targeted Agents for Lymphomas Tr...

In this episode, Enriqueta Felip, MD, PhD, and Matthew Gubens, MD, MS, discuss evolving practice standards for EGFR -mutated non-small-cell lung cancer with topics including: Biomarker testing and strategies Optimal first-line therapy in patients with NSCLC Management of patients with CNS disease Selecting therapy for patients with noncanonical mutations Management strategies after progression on...

In this episode, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, interpret the latest clinical data on targeting FGFR in urothelial cancer     Presenters: Ignacio Durán, MD, PhD Associate Professor GU Oncology Program Leader Department of Medical Oncology Hospital Universitario Marques de Valdecilla-Idival Santander, Spain Alison Birtle, MD, FRCP, FRCR Honorary Senior Lecturer Faculty o...

In this episode, Michael J. Pishvaian, MD, PhD, and Rachna Shroff, MD, answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in pancreatic cancer treatment, with questions including: What is your preferred regimen for neoadjuvant therapy in patients with resectable disease? How do you sequence therapy for patients with metastatic pancreatic can...

In this episode, Frederick L. Locke, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with lymphomas, with questions including: How does the recent approval of lisocabtagene maraleucel and the expanded indication for axicabtagene ciloleucel add to the treatment landscape for DLBCL?  Do you see CAR T-cell therapy eve...

In this episode, D. Ross Camidge, MD, PhD, and Joel W. Neal, MD, PhD, answer questions on investigational antibody-drug conjugates for advanced NSCLC   Presenters: Ross Camidge, MD, PhD   Professor of Medicine/Oncology   University of Colorado Cancer Center Aurora, Colorado Joel W. Neal, MD, PhD   Associate Professor of Medicine Division of Oncology Department of Medicine Stanford University Atten...

In this episode, Noopur Raje, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with multiple myeloma and key toxicities associated with CAR T-cell therapy, with questions including: Now that belantamab mafodotin is approved for relapsed/refractory multiple myeloma, what are your thoughts on how BCMA-directed CAR T-c...

In this episode, Dr. Shaji Kumar from the Mayo Clinic and Dr. Sagar Lonial from Emory University discuss highlights of the key data from ASH 2020 on the treatment of patients with multiple myeloma. Topics include: Newly diagnosed multiple myeloma Relapsed/refractory multiple myeloma Anti-BCMA therapy: CAR T-cells Anti-BCMA therapy: bispecific antibodies Anti-BCMA therapy: antibody–drug conjugates...

In this episode, Jorge Cortes, MD, and Eunice S. Wang, MD, discuss the clinical implications of 3 key studies in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) presented at the virtual ASH 2020 annual conference. Topics include:   The macrophage immune checkpoint inhibitor magrolimab in AML The STAMP inhibitor asciminib in CML (the ASCEMBL trial) Optimal dosing for the TKI ponatin...

In this episode, Jamie E. Chaft, MD, provides her expert perspective on new data from WCLC 2020 in early-stage NSCLC, with topics including: Updated results from ADAURA on HRQoL and DFS outcomes with or without postoperative chemotherapy after adjuvant osimertinib An analysis of the ongoing ITACA study of personalizing chemotherapy based on biomarkers of drug resistance FDG PET/CT adaptive radioth...

In this episode, José Ignacio Nolazco, MD, and Alejandro Nolazco, MD, discuss in Spanish the latest immuno-oncology developments in the treatment of urothelial cancer from an Argentinian perspective.   Presenters: José Ignacio Nolazco, MD   Urology Fellow Hospital Universitario Austral Buenos Aires, Argentina Alejandro Nolazco, MD Associate Professor Department of Urology Universidad Austral and U...

In this episode, Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD, provide their clinical perspectives on new data from ASH 2020 on nonmalignant hematologic disorders, with topics including: Use of mycophenolate mofetil plus corticosteroids vs standard corticosteroid treatment in patients with ITP from the phase III FLIGHT study  Analysis of an ongoing phase I/II trial of rilzabrut...

In this episode, Amy E. DeZern, MD, MHS, and Srdan Verstovsek, MD, provide medical oncology and hematology perspectives on new data from ASH 2020 in MDS and MPNs, with topics including: 3-year OS results with RIC allogeneic transplantation in patients with higher-risk MDS in the BMT CTN 1102 study A post hoc analysis of phase II data on the addition of pevonedistat to azacitidine in higher-risk MD...

In this episode, Guiseppe Procopio, MD, and Cora N. Sternberg, MD, FACP, discuss in Italian the latest immuno-oncology developments in the treatment of urothelial cancer.   Presenters: Guiseppe Procopio, MD   Head of the Medical Oncology Genitourinary, Istituto Nazionale Tumori Medical Oncology Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy Cora N. Sternberg, MD, FACP Professor of Med...

In this episode, Michael Callaghan, MD; Miguel A. Escobar, MD; and Rebecca Kruse-Jarres, MD, MPH, answer questions from a clinician audience on topics related to hemophilia management including: Maintaining long-term musculoskeletal health Identifying patients most likely to benefit from pharmacokinetics-guided prophylaxis Managing combination therapies in older patients with comorbidities Younges...

In this episode, Petros Grivas, MD, PhD, and Jonathan E. Rosenberg, MD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in the United States. Topics include: Guideline changes for first-line UC based on data from JAVELIN Bladder 100 trial on avelumab maintenance after chemotherapy Results from IMvigor130 and KEYNOTE-361 trials on concurre...

Link to CME: Claim Credit In this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, discuss key considerations in the contemporary use of immune checkpoint inhibitors for treating patients with advanced hepatocellular carcinoma, with topics including: Optimal use of the newly approved immune checkpoint inhibitor/VEGF inhibitor combination of atezolizumab plus bevacizumab Use of nivolumab ± ip...

In this episode, Félix Guerrero Ramos, MD, PhD, FEBU, and Óscar Rodríguez-Faba, MD, discuss in Spanish the latest immuno-oncology developments in the treatment of urothelial cancer.  Presenters: Félix Guerrero Ramos, MD, PhD, FEBU  Teaching Collaborator Department of Surgery Medicine School Universidad Complutense de Madrid Attending Urologist Department of Urology UroOncology Unit Madrid, Spain ...

In this episode, Nathan Pennell, MD, PhD, and Laura J. Tafe, MD, provide medical oncology and pathology perspectives, respectively, when answering questions from a clinician audience on topics including: Next steps in patient care after identifying a biomarker: selecting treatment, getting insurance approval, arranging for financial assistance Performing biomarker testing on cytology vs surgical o...

In this episode,William G. Wierda, MD, PhD, Jeremy S. Abramson, MD, MMSc, and Brian Hill, MD, PhD, answer questions focused on personalizing therapy for patients with CLL considering patient characteristics and currently available clinical evidence. Presenters: William G. Wierda, MD, PhD, Program Director Professor of Medicine Chief , Section of CLL Department of Leukemia The University of Texas M...

In this episode, Helena A. Yu, MD, and Maria E. Arcila, MD, provide medical oncology and pathology perspectives, respectively, on new data from ESMO 2020 informing precision medicine in NSCLC, with topics including: Updated efficacy data from the phase III ADAURA study of adjuvant osimertinib for resected EGFR-mutated NSCLC with a focus on CNS disease recurrence Biomarker testing in early-stage lu...

Link to CME: Claim Credit In this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, answer clinician questions on current best practices and emerging applications  with immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma, with topics including: Optimal use of the newly approved immune checkpoint inhibitor/VEGF inhibitor combination of atezolizumab plus bevacizumab...

In this episode, Thomas Powles, MBBS, MRCP, MD, and Michiel van der Heijden, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in the United Kingdom and the Netherlands. Topics include: Data from registrational trials in the European Union for pembrolizumab and atezolizumab in the first-line/second-line settings Utility of PD-L1 an...

In this episode, Alain Ravaud, MD, PhD, and Marine Gross-Goupil, MD, PhD, discuss in French the latest immuno-oncology developments in the treatment of urothelial cancer.  Presenters: Alain Ravaud, MD, PhD   Professor of Medical Oncology Head of Department of Medical Oncology Bordeaux University Hospital Bordeaux, France Marine Gross-Goupil, MD, PhD   Medical Oncologist Saint-André Hospital Bordea...

In this episode, Mansoor Raza Mirza, MD, and Ana Oaknin, MD, PhD, discuss the implications of recent advances in the use of molecular testing and classification to guide the use of immunotherapy for the treatment of patients with endometrial cancer.   Presenters: Ana Oaknin, MD, PhD Head of Gynecologic Tumors Unit Medical Oncology Department Vall d´Hebron University Hospital Barcelona, Spain   Man...